Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

The board of directors for 23andMe quit following disagreements over the CEO's plans to privatize the DNA testing company.

SUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health ...

The history of the DNA-testing startup reads like a checklist of Silicon Valley clichés: founder squabbles, gobs of cash, a ...

On Sept. 23, the board of directors at 23andMe, a prominent DNA testing company, announced their resignation following a series of disagreements with CEO Ann ...

All of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the ...

Personal information for nearly half of the popular genetic testing company's customers -- 6.9 million people -- were exposed ...

The pioneering DNA testing firm has been struggling to stay afloat financially despite ambitious ventures to provide health ...

Me's entire board of directors resigned over cofounder and CEO Anne Wojcicki's ongoing plan to take it private.

The board of Anne Wojcicki's genetic-testing company resigned earlier this week. This founder thinks he has a plan to save ...

Me has agreed to pay $30 million after a class action suit was brought against the company for last year's data breach.

All seven of 23andMe’s independent board members resigned in a stinging rebuke to a proposal by CEO Anne Wojcicki’s plans to to take the company private. Wojcicki, who has been trying to take the ...